Positioning of proteasome inhibitors in therapy of solid malignancies

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received con...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology Vol. 81; no. 2; pp. 227 - 243
Main Authors: Roeten, Margot S. F., Cloos, Jacqueline, Jansen, Gerrit
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2018
Springer Nature B.V
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cancer Research
Colon
Cytotoxic Reviews
Drug Resistance, Neoplasm
Head & neck cancer
Humans
Medicine
Medicine & Public Health
Molecular modelling
Neoplasms - drug therapy
Oncology
Pancreas
Pharmacology/Toxicology
Protease inhibitors
Proteasome Endopeptidase Complex - chemistry
Proteasome Endopeptidase Complex - drug effects
Proteasome inhibitors
Proteasome Inhibitors - pharmacology
Proteasome Inhibitors - therapeutic use
Proteasomes
Review
Review Article
Solid tumors
Targeted cancer therapy
Ubiquitin
Carfilzomib
Bortezomib
Solid tumors
Drug resistance
Proteasome inhibitors
ISSN:0344-5704, 1432-0843, 1432-0843
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ISSN:0344-5704
1432-0843
1432-0843
DOI:10.1007/s00280-017-3489-0